Latest Equities News

Westpac Banking Corporation reported a solid $6.9 billion net profit for FY25, underpinned by strong deposit growth and ongoing digital transformation, while advancing ambitious sustainability targets.

Westpac reported a resilient full-year 2025 performance with modest profit decline, robust loan and deposit growth, and ongoing strategic initiatives aimed at simplifying operations and enhancing customer experience.

Westpac Banking Corporation reported a solid $6.9 billion statutory net profit for 2025, maintaining strong capital and credit quality while increasing dividends. The bank’s ongoing transformation and disciplined growth underpin its outlook amid evolving economic conditions.

Westpac Banking Corporation reported a slight 1% decline in net profit to $6.916 billion for 2025, while maintaining a strong capital position and progressing its UNITE transformation program. The bank declared a fully franked final dividend of 77 cents per share, underscoring its commitment to shareholder returns amid ongoing economic challenges.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

Horseshoe Metals has secured mining approval for Direct Shipping Ore operations at its Horseshoe Lights project, complemented by promising drilling assays and strategic funding to accelerate development.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

NT Minerals Limited reported a net cash outflow of A$590,000 for Q3 2025 but bolstered its liquidity with A$1.07 million from investing activities, leaving it with over two quarters of funding runway.

Resources & Energy Group Limited (REZ) has secured approval to expand gold vat leach production at its East Menzies Gold Project, transitioning from trial to commercial scale. The company also announced a maiden JORC 2012 Inferred Mineral Resource at Gigante Grande, underpinning future growth.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

Challenger Gold Limited advances its Hualilan Gold Project with commissioning of the Casposo Toll Milling plant and key operational contracts, while Ecuador projects gain value following Lumina Gold’s takeover. A $30 million placement strengthens funding for upcoming milestones.

Nexion Group has completed the sale of its networks business for $4.1 million, marking a strategic pivot towards data centre operations and its AI-driven FuseAI software platform. The company is restructuring and preparing to resume ASX trading amid evolving revenue streams.